Deutsche Bank
ALNY icon

Deutsche Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

Deutsche Bank’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.13M Hold
10,400
– – ﹤0.01% 1645
2026
Q1 		$3.44M Hold
10,400
– – ﹤0.01% 1492
2025
Q4 		$4.14M Buy
10,400
+2,200
+27% +$974K ﹤0.01% 1397
2025
Q3 		$3.74M Buy
+8,200
New +$3.34M ﹤0.01% 1444
2024
Q3 		– Sell
-8,700
Closed -$2.11M – 3606
2024
Q2 		$2.11M Buy
+8,700
New +$1.37M ﹤0.01% 1609
2014
Q3 		– Sell
-368
Closed -$23K – 5871
2014
Q2 		$23K Sell
368
-632
-63% -$37.6K ﹤0.01% 5260
2014
Q1 		$4K Buy
+1,000
New +$77.4K ﹤0.01% 5212

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deutsche Bank's ALNY Position: Q2 2026 in Review

Deutsche Bank increased its Alnylam Pharmaceuticals (ALNY) stake by 7.1% in Q2 2026, buying an estimated $16.3M and bringing the position to 815,400 shares worth $245M. The position accounts for 0.07% of the portfolio, ranked #244.

Deutsche Bank first reported a position in ALNY in Q2 2013 and has held it in 53 quarters since. The position peaked at $283M in Q4 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Deutsche Bank held 815,400 shares of Alnylam Pharmaceuticals worth $245M as of Q2 2026.
  • Deutsche Bank bought 53,936 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $16.3M.
  • Alnylam Pharmaceuticals made up 0.07% of Deutsche Bank's portfolio in Q2 2026, its #244 holding.
  • Deutsche Bank first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Deutsche Bank's Alnylam Pharmaceuticals position peaked at $283M in Q4 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.